Meeting
2024 ASCO Annual Meeting
Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Authors
Kerin B. Adelson
The University of Texas MD Anderson Cancer Center, Houston, TX
Kerin B. Adelson , Lee Cheng , Yu-Ting Huang , Jiangong Niu , Hui Zhao , Nico Nortje , Jenny Jing Xiang , Sharon H. Giordano , Maureen Canavan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Quality Care/Health Services Research
Track
Care Delivery and Quality Care
Sub Track
Health Services Research
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 11092)
DOI
10.1200/JCO.2024.42.16_suppl.11092
Abstract #
11092
Poster Bd #
287
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM).
First Author: Maureen Canavan
Poster
2024 ASCO Annual Meeting
Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).
First Author: Jung-Yun Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
First Author: Timothy J Brown